Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec;34(12):2601-2604.
doi: 10.1007/s00467-019-04341-4. Epub 2019 Sep 13.

Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature

Affiliations
Review

Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature

Orly Haskin et al. Pediatr Nephrol. 2019 Dec.

Abstract

Background: Eculizumab has caused a revolution in the treatment and prognosis of atypical hemolytic uremic syndrome. Early initiation of treatment is recommended to increase chances of renal recovery.

Case-diagnosis/treatment: We describe a boy with atypical hemolytic uremic syndrome who started eculizumab therapy after being on dialysis for 4.5 months, with complete anuria. With treatment, he was weaned off dialysis.

Conclusion: We review the evidence in the literature and discuss the possible mechanism by which eculizumab induces renal recovery even in patients already on prolonged dialysis. This case report highlights the importance of a treatment trial with eculizumab, even in patients already on prolonged dialysis.

Keywords: Child; Dialysis; Eculizumab; aHUS.

PubMed Disclaimer

References

    1. Pediatr Nephrol. 2004 Apr;19(4):419-25 - PubMed
    1. Clin J Am Soc Nephrol. 2013 Apr;8(4):554-62 - PubMed
    1. Clin Kidney J. 2012 Feb;5(1):34-6 - PubMed
    1. Kidney Int. 2018 Aug;94(2):408-418 - PubMed
    1. Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1510-1516 - PubMed

Substances

LinkOut - more resources